在ER阳性乳腺癌中使用新辅助内分泌疗法:演变,指示和量身定制的治疗策略
1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Therapeutic advances in medical oncology
|October 3, 2023
概括
对雌激素受体阳性乳腺癌的新辅助内分泌疗法 (NET) 对瘤缩和预测患者结果有希望. 这种方法还有助于评估新疗法和个性化术后护理.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 临床试验 临床试验
背景情况:
- 雌激素受体 (ER) 阳性乳腺癌的管理.
- 内分泌疗法 (ET) 作为全身治疗.
- 对新辅助性内分泌疗法 (NET) 的兴趣日益增长.
研究的目的:
- 审查NET的现有证据.
- 讨论NET试验的演变.
- 概述NET的临床征兆和治疗策略.
主要方法:
- 最近的试验和证据的文献综述.
- 临床和分子生物标志物的分析.
- 讨论新辅助系统治疗的目标.
主要成果:
- ET在ER阳性乳腺癌的瘤缩小方面表现出有效性.
- NET为患者预后提供了对内分泌敏感性的见解.
- NET允许早期评估新药的疗效.
结论:
- NET是一种有价值的新辅助策略,用于ER阳性乳腺癌.
- 生物标志物驱动的方法使得定制的术后管理成为可能.
- 对NET的临床适应症正在扩大,支持个性化治疗.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Cancer Survival Analysis
380
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
380
Tumor Immunotherapy
551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551


